| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hua Bai, Bo Yang, Wenfeng Yu, Yan Xiao, Dejun Yu, Qifang Zhan. Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome. Experimental cell research. vol 362. issue 1. 2018-09-07. PMID:29196167. |
oxidative stress-mediated activation of nlrp3 inflammasome in microglia is critical in the development of neurodegerative diseases such as alzheimer's disease (ad), parkinson disease (pd). |
2018-09-07 |
2023-08-13 |
Not clear |
| Michael J D Daniels, Jack Rivers-Auty, Tom Schilling, Nicholas G Spencer, William Watremez, Victoria Fasolino, Sophie J Booth, Claire S White, Alex G Baldwin, Sally Freeman, Raymond Wong, Clare Latta, Shi Yu, Joshua Jackson, Nicolas Fischer, Violette Koziel, Thierry Pillot, James Bagnall, Stuart M Allan, Pawel Paszek, James Galea, Michael K Harte, Claudia Eder, Catherine B Lawrence, David Broug. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nature communications. vol 7. 2018-09-05. PMID:27509875. |
fenamate nsaids inhibit the nlrp3 inflammasome and protect against alzheimer's disease in rodent models. |
2018-09-05 |
2023-08-13 |
mouse |
| Michael J D Daniels, Jack Rivers-Auty, Tom Schilling, Nicholas G Spencer, William Watremez, Victoria Fasolino, Sophie J Booth, Claire S White, Alex G Baldwin, Sally Freeman, Raymond Wong, Clare Latta, Shi Yu, Joshua Jackson, Nicolas Fischer, Violette Koziel, Thierry Pillot, James Bagnall, Stuart M Allan, Pawel Paszek, James Galea, Michael K Harte, Claudia Eder, Catherine B Lawrence, David Broug. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nature communications. vol 7. 2018-09-05. PMID:27509875. |
these data suggest that fenamate nsaids could be repurposed as nlrp3 inflammasome inhibitors and alzheimer's disease therapeutics. |
2018-09-05 |
2023-08-13 |
mouse |
| Marine Groslambert, Bénédicte F P. [Regulation of the NLRP3 inflammasome]. Medecine sciences : M/S. vol 34. issue 1. 2018-08-31. PMID:29384096. |
moreover, inappropriate nlrp3 activation causes deleterious inflammation and contributes to various conditions including atherosclerosis, diabetes, gout and alzheimer's diseases. |
2018-08-31 |
2023-08-13 |
Not clear |
| Shao-Jun Li, Yu-Fen Zhang, Se-Hui Ma, Yao Yi, Hong-Yan Yu, Lei Pei, Dan Fen. The role of NLRP3 inflammasome in stroke and central poststroke pain. Medicine. vol 97. issue 33. 2018-08-24. PMID:30113480. |
nlrp3 inflammasome plays a prominent role in the pathogenesis and progression of many diseases, such as type 2 diabetes mellitus, obesity, atherosclerosis, and alzheimer's disease. |
2018-08-24 |
2023-08-13 |
Not clear |
| Su-Chen Ho, Yi-Huang Chan. Comparison of Inhibitory Capacities of 6-, 8- and 10-Gingerols/Shogaols on the Canonical NLRP3 Inflammasome-Mediated IL-1β Secretion. Molecules (Basel, Switzerland). vol 23. issue 2. 2018-08-22. PMID:29466287. |
endogenous noninfectious substances that mediate the nucleotide oligomerization domain (nod)-like receptor family pyrin domain-containing 3 (nlrp3) inflammasome activation and interleukin (il)-1β secretion causes inappropriate sterile inflammation and is implicated in the pathogenesis of several chronic diseases, such as type 2 diabetes mellitus, gout, atherosclerosis and alzheimer's disease. |
2018-08-22 |
2023-08-13 |
Not clear |
| Malihe Aminzadeh, Mehrdad Roghani, Azadeh Sarfallah, Gholam Hossein Riaz. TRPM2 dependence of ROS-induced NLRP3 activation in Alzheimer's disease. International immunopharmacology. vol 54. 2018-07-25. PMID:29107864. |
trpm2 dependence of ros-induced nlrp3 activation in alzheimer's disease. |
2018-07-25 |
2023-08-13 |
Not clear |
| Eileen M Martinez, Alison L Young, Yash R Patankar, Brent L Berwin, Li Wang, Katharine M von Herrmann, Jaclyn M Weier, Matthew C Havrd. Editor's Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice. Toxicological sciences : an official journal of the Society of Toxicology. vol 159. issue 1. 2018-06-19. PMID:28903492. |
reports by others indicating that nlrp3 expression was detectable in tissues obtained from alzheimer's disease patients and that the pd-associated protein α-synuclein could activate inflammasomes in cultured glial cells, prompted us to test the prediction that nlrp3 was required for the development of parkinson's-like changes resulting from rotenone exposure in mice. |
2018-06-19 |
2023-08-13 |
mouse |
| Mohammad Ejaz Ahmed, Shankar Iyer, Ramasamy Thangavel, Duraisamy Kempuraj, Govindhasamy Pushpavathi Selvakumar, Sudhanshu P Raikwar, Smita Zaheer, Asgar Zahee. Co-Localization of Glia Maturation Factor with NLRP3 Inflammasome and Autophagosome Markers in Human Alzheimer's Disease Brain. Journal of Alzheimer's disease : JAD. vol 60. issue 3. 2018-05-30. PMID:28984607. |
co-localization of glia maturation factor with nlrp3 inflammasome and autophagosome markers in human alzheimer's disease brain. |
2018-05-30 |
2023-08-13 |
human |
| Zhou Lan, Guangjing Xie, Meng Wei, Ping Wang, Lvyi Che. The protective effect of Epimedii Folium and Curculiginis Rhizoma on Alzheimer's disease by the inhibitions of NF-κB/MAPK pathway and NLRP3 inflammasome. Oncotarget. vol 8. issue 27. 2018-03-29. PMID:28582770. |
the protective effect of epimedii folium and curculiginis rhizoma on alzheimer's disease by the inhibitions of nf-κb/mapk pathway and nlrp3 inflammasome. |
2018-03-29 |
2023-08-13 |
rat |
| Claire S White, Catherine B Lawrence, David Brough, Jack Rivers-Aut. Inflammasomes as therapeutic targets for Alzheimer's disease. Brain pathology (Zurich, Switzerland). vol 27. issue 2. 2018-03-05. PMID:28009077. |
inflammasomes, which regulate il-1β release, are formed following activation of cytosolic prrs, and using genetic and pharmacological approaches, nlrp3 and nlrp1 inflammasomes have been found to be integral in pathogenic neuroinflammation in animal models of alzheimer's disease. |
2018-03-05 |
2023-08-13 |
Not clear |
| Alex G Baldwin, Jack Rivers-Auty, Michael J D Daniels, Claire S White, Carl H Schwalbe, Tom Schilling, Halah Hammadi, Panichakorn Jaiyong, Nicholas G Spencer, Hazel England, Nadia M Luheshi, Manikandan Kadirvel, Catherine B Lawrence, Nancy J Rothwell, Michael K Harte, Richard A Bryce, Stuart M Allan, Claudia Eder, Sally Freeman, David Broug. Boron-Based Inhibitors of the NLRP3 Inflammasome. Cell chemical biology. vol 24. issue 11. 2017-12-26. PMID:28943355. |
nlrp3 is a receptor important for host responses to infection, yet is also known to contribute to devastating diseases such as alzheimer's disease, diabetes, atherosclerosis, and others, making inhibitors for nlrp3 sought after. |
2017-12-26 |
2023-08-13 |
Not clear |
| Alon Simchovitz, Michael T Heneka, Hermona Sore. Personalized genetics of the cholinergic blockade of neuroinflammation. Journal of neurochemistry. vol 142 Suppl 2. 2017-09-07. PMID:28326544. |
since cholinergic signaling blocks neuroinflammation which is inherent to alzheimer's disease, genomic changes modifying ache's properties and its susceptibility to inhibitors and/or to cholinomirs regulation may affect the levels and properties of inflammasome components such as nlrp3. |
2017-09-07 |
2023-08-13 |
Not clear |
| Mattia Cocco, Gianluca Miglio, Marta Giorgis, Davide Garella, Elisabetta Marini, Annalisa Costale, Luca Regazzoni, Giulio Vistoli, Marica Orioli, Raïhane Massulaha-Ahmed, Isabelle Détraz-Durieux, Marine Groslambert, Bénédicte F Py, Massimo Bertinari. Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors. ChemMedChem. vol 11. issue 16. 2017-06-06. PMID:26990578. |
the overactivation of nlrp3 is implicated in the pathogenesis of autoinflammatory diseases, known as cryopyrin-associated periodic syndromes (caps), and in the progression of several diseases, such as atherosclerosis, type-2 diabetes, gout, and alzheimer's disease. |
2017-06-06 |
2023-08-13 |
human |
| Je-Wook Yu, Myung-Shik Le. Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Archives of pharmacal research. vol 39. issue 11. 2017-01-30. PMID:27600432. |
activation of the nlrp3 inflammasome by endogenous ligands has been discovered in various disorders, including metabolic syndrome, type 2 diabetes, atherosclerosis, gout, reperfusion injury of the heart, neurodegeneration, such as alzheimer's disease, chronic kidney diseases, and macular degeneration of the eyes. |
2017-01-30 |
2023-08-13 |
Not clear |
| Marina Saresella, Francesca La Rosa, Federica Piancone, Martina Zoppis, Ivana Marventano, Elena Calabrese, Veronica Rainone, Raffaello Nemni, Roberta Mancuso, Mario Cleric. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Molecular neurodegeneration. vol 11. 2016-11-08. PMID:26939933. |
the nlrp3 and nlrp1 inflammasomes are activated in alzheimer's disease. |
2016-11-08 |
2023-08-13 |
Not clear |
| Alex G Baldwin, David Brough, Sally Freema. Inhibiting the Inflammasome: A Chemical Perspective. Journal of medicinal chemistry. vol 59. issue 5. 2016-08-23. PMID:26422006. |
inappropriate activation of the nlrp3 inflammasome contributes to the progression of many noncommunicable diseases such as gout, type ii diabetes, and alzheimer's disease. |
2016-08-23 |
2023-08-13 |
Not clear |
| Jonathan L Schmid-Burgk, Dhruv Chauhan, Tobias Schmidt, Thomas S Ebert, Julia Reinhardt, Elmar Endl, Veit Hornun. A Genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Screen Identifies NEK7 as an Essential Component of NLRP3 Inflammasome Activation. The Journal of biological chemistry. vol 291. issue 1. 2016-05-17. PMID:26553871. |
to this effect, several studies have identified nlrp3 inflammasome engagement in a number of common human diseases such as atherosclerosis, type 2 diabetes, alzheimer disease, or gout. |
2016-05-17 |
2023-08-13 |
mouse |
| Rebecca C Coll, Avril A B Robertson, Jae Jin Chae, Sarah C Higgins, Raúl Muñoz-Planillo, Marco C Inserra, Irina Vetter, Lara S Dungan, Brian G Monks, Andrea Stutz, Daniel E Croker, Mark S Butler, Moritz Haneklaus, Caroline E Sutton, Gabriel Núñez, Eicke Latz, Daniel L Kastner, Kingston H G Mills, Seth L Masters, Kate Schroder, Matthew A Cooper, Luke A J O'Neil. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature medicine. vol 21. issue 3. 2015-05-01. PMID:25686105. |
the nod-like receptor (nlr) family, pyrin domain-containing protein 3 (nlrp3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-associated periodic syndrome (caps) and complex diseases such as multiple sclerosis, type 2 diabetes, alzheimer's disease and atherosclerosis. |
2015-05-01 |
2023-08-13 |
mouse |
| Glenn J Rapsinski, Meghan A Wynosky-Dolfi, Gertrude O Oppong, Sarah A Tursi, R Paul Wilson, Igor E Brodsky, Çagla Tüke. Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infection and immunity. vol 83. issue 2. 2015-04-28. PMID:25422268. |
interestingly, activation of the nlrp3 inflammasome by curli fibers or by amyloid β of alzheimer's disease does not cause cell death in macrophages. |
2015-04-28 |
2023-08-13 |
human |